Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Conditions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 52
- Registration Number
- NCT00836901
- Locations
- 🇨🇦
Anapharm Inc., Montreal, Quebec, Canada
Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00836004
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Clarithromycin 500 mg Tablets Under Fasting Conditions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT00835692
- Locations
- 🇺🇸
PRACS Institute Ltd, Fargo, North Dakota, United States
Benazepril HCl 40 mg Tablets, Fed
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 40
- Registration Number
- NCT00836537
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Finasteride 5 mg Tablets, Non-fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 20
- Registration Number
- NCT00835796
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00836056
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 68
- Registration Number
- NCT00835367
- Locations
- 🇨🇦
Anapharm Inc., Montreal, Quebec, Canada
🇨🇦SFBC Anapharm, Sainte-Foy, Quebec, Canada
15 mg Mirtazapine Orally Disintegrating Tablets, Fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00835575
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Granisetron 1 mg Tablets, Non-fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 80
- Registration Number
- NCT00834522
- Locations
- 🇨🇦
Pharma Medica Research Inc, Toronto, Ontario, Canada
Leflunomide 20 mg Tablets, Non-Fasting
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 37
- Registration Number
- NCT00834405
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
🇺🇸Bioassay Laboratory, Inc., Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath